After reviewing Neonc Technologies Holdings' CMC (Chemistry, Manufacturing, and Controls) development plan, the US Food and Drug Administration (FDA) considers the overall approach reasonable.

However, regulators have imposed additional conditions regarding changes in the production process, requiring the company to meet specific requirements when implementing related adjustments. This feedback provides important guidance for Neonc's drug development process. CMC development is a critical aspect of drug approval and commercialization, involving core areas such as production technology, quality control, and stability. The FDA's approval signifies that the company’s technical path in this field is basically endorsed, while the additional conditions clarify the regulatory framework that must be followed during subsequent production optimization.For investors, this news may be seen as a positive signal, indicating that the company’s R&D efforts are advancing along a path recognized by regulators. At the same time, specifying the conditions for production changes helps reduce uncertainty in future submissions and lays a foundation for the final commercialization of the product.